Lunai Bioworks (NASDAQ:LNAI) Lowered to “Sell” Rating by Wall Street Zen

Lunai Bioworks (NASDAQ:LNAI) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Lunai Bioworks in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Lunai Bioworks Trading Down 5.5%

LNAI opened at $0.55 on Friday. The firm has a fifty day moving average of $0.87. Lunai Bioworks has a 1-year low of $0.52 and a 1-year high of $14.00. The company has a market capitalization of $13.19 million, a P/E ratio of -7.79 and a beta of 0.46.

Lunai Bioworks (NASDAQ:LNAI) last issued its earnings results on Tuesday, February 17th. The company reported ($0.08) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lunai Bioworks stock. Millennium Management LLC purchased a new stake in Lunai Bioworks Inc. (NASDAQ:LNAI) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks at the end of the most recent quarter. 71.41% of the stock is currently owned by institutional investors and hedge funds.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.